Immune competence after alemtuzumab treatment of multiple sclerosis
نویسندگان
چکیده
منابع مشابه
Immune competence after alemtuzumab treatment of multiple sclerosis.
OBJECTIVE To determine the immunocompetency of patients with multiple sclerosis treated with the lymphodepleting humanized monoclonal antibody alemtuzumab. METHODS In this pilot case-control study, we assessed immunocompetence in 24 patients after alemtuzumab treatment by measuring antibody responses to 3 vaccines (diphtheria, tetanus, and poliomyelitis vaccine, Haemophilus influenzae type b ...
متن کاملImmune Rebound: Multiple Sclerosis after Treatment of Cushing’s disease
High cortisol level in endogenous Cushing’s syndrome suppresses the immune system and after treatment there may be an over activity of immune reaction leading to autoimmune diseases mostly thyroid and rheumatologic disorders. This is the second reported case of multiple sclerosis developing after treatment of Cushing’s syndrome. A 42-year old man is reported who presented with bone fracture and...
متن کاملAlemtuzumab treatment alters circulating innate immune cells in multiple sclerosis
OBJECTIVE To characterize changes in myeloid and lymphoid innate immune cells in patients with relapsing-remitting multiple sclerosis (MS) during a 6-month follow-up after alemtuzumab treatment. METHODS Circulating innate immune cells including myeloid cells and innate lymphoid cells (ILCs) were analyzed before and 6 and 12 months after onset of alemtuzumab treatment. Furthermore, a potential...
متن کاملPredicting autoimmunity after alemtuzumab treatment of multiple sclerosis.
OBJECTIVE We have previously shown that autoimmunity following alemtuzumab treatment of multiple sclerosis can be predicted by high baseline serum interleukin IL-21 (IL-21), as measured using a now 'redundant' enzyme linked immunosorbent assay (ELISA). Here we ask whether currently available ELISAs have similar prognostic value. DESIGN Serum IL-21 from 141 individuals with relapsing remitting...
متن کاملGraves' disease after treatment with alemtuzumab for multiple sclerosis.
CONTEXT Alemtuzumab, a humanized monoclonal antibody against CD52, is effective in the treatment of early relapsing-remitting multiple sclerosis (MS). Common adverse effects include an acute-phase reaction, infections and autoimmune diseases, including thyroid disorders. SETTING Patients from two phase 3 trials (CARE MS 1 and 2, n=15) were studied in a clinical research center. PATIENTS Fiv...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurology
سال: 2013
ISSN: 0028-3878,1526-632X
DOI: 10.1212/wnl.0b013e3182a35215